Adherence to evidence-based guidelines for the management of pneumonia in a tertiary teaching hospital in Riyadh.

Adherence Antibiotics Guidelines Management Pneumonia

Journal

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
ISSN: 1319-0164
Titre abrégé: Saudi Pharm J
Pays: Saudi Arabia
ID NLM: 9705695

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 26 03 2023
accepted: 13 06 2023
medline: 14 7 2023
pubmed: 14 7 2023
entrez: 14 7 2023
Statut: ppublish

Résumé

Adherence to therapeutic guidelines is crucial when treating pneumonia, as it reduces mortality rate, length of hospital stay and duration of antibiotic therapy. However, the high non-adherence rate to treatment guidelines, in general, and to the Infectious Disease Society of America (IDSA) guidelines, are still reported globally. According to our knowledge, no existing data is available regarding the rate of physicians' adherence to the IDSA guidelines for managing pneumonia in Saudi Arabia. Therefore, we aim to assess the adherence rate and the clinical outcomes among patients treated according to the IDSA guidelines, in a tertiary care center in Riyadh. A single-centered, retrospective, cross-sectional, observational study was conducted at King Khalid University Hospital, Riyadh, Saudi Arabia. All data were extracted from the hospital's electronic information system, known as Esihi. Adult patients (≥18 years old) diagnosed and treated in the hospital for community-acquired pneumonia, hospital-acquired pneumonia, or ventilator-associated pneumonia from Nov 2019 to Nov 2021 were included. A total of 148 patients were included in this study, and the management of 50% of them (74 patients) adhered to the guidelines' recommendations. Even though the patients who received guidelines-adhered management were older (70 ± 16 vs 59 ± 22; p = 0.001), and had a higher CURB-65 score for pneumonia severity (1.86 ± 1.03 vs 1.39 ± 1.26; p = 0.026) and an average calculated Charlson comorbidity index (4.62 ± 2.19 vs 3.28 ± 2.80; p = 0.001) than patients who were treated irrespectively of the guidelines, yet they had a better cure rate (95% vs 84%; adjusted OR, 3.9; 95% CI, 0.82-18.58), lower mortality (5% vs 14%; adjusted OR, 0.38; 95% CI, 0.04-4.05) and shorter length of hospital stay (LOS) (6.5 vs 8 days; p = 0.082); compared to patients who were treated irrespectively of the guidelines. Comparable to previous literature, non-adherence to evidence-based guidelines has been observed in 50% of patients treated for pneumonia. Despite being nonsignificant, higher clinical cure rates, shorter LOS, and lower mortality rates have been observed in patients who were treated based on evidence-based guidelines. Further measures to improve guidelines compliance in pneumonia treatment are needed.

Sections du résumé

Background UNASSIGNED
Adherence to therapeutic guidelines is crucial when treating pneumonia, as it reduces mortality rate, length of hospital stay and duration of antibiotic therapy. However, the high non-adherence rate to treatment guidelines, in general, and to the Infectious Disease Society of America (IDSA) guidelines, are still reported globally. According to our knowledge, no existing data is available regarding the rate of physicians' adherence to the IDSA guidelines for managing pneumonia in Saudi Arabia. Therefore, we aim to assess the adherence rate and the clinical outcomes among patients treated according to the IDSA guidelines, in a tertiary care center in Riyadh.
Methods UNASSIGNED
A single-centered, retrospective, cross-sectional, observational study was conducted at King Khalid University Hospital, Riyadh, Saudi Arabia. All data were extracted from the hospital's electronic information system, known as Esihi. Adult patients (≥18 years old) diagnosed and treated in the hospital for community-acquired pneumonia, hospital-acquired pneumonia, or ventilator-associated pneumonia from Nov 2019 to Nov 2021 were included.
Results UNASSIGNED
A total of 148 patients were included in this study, and the management of 50% of them (74 patients) adhered to the guidelines' recommendations. Even though the patients who received guidelines-adhered management were older (70 ± 16 vs 59 ± 22; p = 0.001), and had a higher CURB-65 score for pneumonia severity (1.86 ± 1.03 vs 1.39 ± 1.26; p = 0.026) and an average calculated Charlson comorbidity index (4.62 ± 2.19 vs 3.28 ± 2.80; p = 0.001) than patients who were treated irrespectively of the guidelines, yet they had a better cure rate (95% vs 84%; adjusted OR, 3.9; 95% CI, 0.82-18.58), lower mortality (5% vs 14%; adjusted OR, 0.38; 95% CI, 0.04-4.05) and shorter length of hospital stay (LOS) (6.5 vs 8 days; p = 0.082); compared to patients who were treated irrespectively of the guidelines.
Conclusions UNASSIGNED
Comparable to previous literature, non-adherence to evidence-based guidelines has been observed in 50% of patients treated for pneumonia. Despite being nonsignificant, higher clinical cure rates, shorter LOS, and lower mortality rates have been observed in patients who were treated based on evidence-based guidelines. Further measures to improve guidelines compliance in pneumonia treatment are needed.

Identifiants

pubmed: 37448847
doi: 10.1016/j.jsps.2023.06.011
pii: S1319-0164(23)00168-8
pmc: PMC10336669
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101678

Informations de copyright

© 2023 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
JAC Antimicrob Resist. 2021 Jun 14;3(2):dlab080
pubmed: 34223139
Curr Opin Infect Dis. 2019 Dec;32(6):656-662
pubmed: 31567412
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
Cleve Clin J Med. 2020 Oct 1;87(10):633-639
pubmed: 33004324
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Expert Rev Respir Med. 2019 Jan;13(1):63-77
pubmed: 30518278
Int J Infect Dis. 2006 Jul;10(4):326-33
pubmed: 16678467
Eur J Intern Med. 2015 Jun;26(5):330-7
pubmed: 25898778
BMC Med Inform Decis Mak. 2016 Mar 15;16:34
pubmed: 26976388
Saudi Pharm J. 2022 Mar;30(3):212-216
pubmed: 35498226
Intern Emerg Med. 2016 Oct;11(7):929-40
pubmed: 27098057
BMJ Open Qual. 2019 Apr 24;8(2):e000554
pubmed: 31206061
Clin Infect Dis. 2005 Dec 15;41(12):1709-16
pubmed: 16288392

Auteurs

Mohammed Alessa (M)

Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Thamer A Almangour (TA)

Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Ahmed Alhassoun (A)

Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Ibrahim Alajaji (I)

Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Abdullah Almangour (A)

Department of Clinical Pharmacy, Security Forces Hospital, Riyadh, Saudi Arabia.

Abdulaziz Alsalem (A)

Department of Clinical Pharmacy, Security Forces Hospital, Riyadh, Saudi Arabia.

Abdullah A Alhifany (AA)

Department of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.

Classifications MeSH